- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02810522
OneTouch Select® [Brand Name]Plus Blood Glucose Monitoring System(BGMS) Registration Study
A Registration Study to Assess User Performance of OneTouch Select® Plus Blood Glucose Monitoring System
This study is to support the regulatory application of OneTouch Select® Plus test strips in China. The blood glucose test strip is regulated as an In Vitro Diagnostic (IVD) product and China Food and Drug Administration (CFDA) regulation of IVDs should be complied with. The result of this study will be used to support regulatory filing in China.
Investigational Product:
OneTouch Select® Plus test strips (test with OneTouch Select® Plus glucose meter)
Objectives:
- Assess Lay User and Health Care Professional (HCP) fingertip test results obtained on OneTouch Select® Plus BGMS compared to a validated method (YSI 2300 glucose analyzer results), according to International Standards Organization( ISO) 15197:2003(E) section 8.0 and ISO 15197:2013(E)
- Lay User System Use evaluation.
- Assess the effectiveness of the instructions for use of OneTouch Select® Plus BGMS (Owner's booklet) and insert of test strips for the lay user.
Comparator(control) Product:
YSI 2300 glucose analyser
Acceptance Criteria:
User Performance of the OneTouch Select® Plus Blood Glucose Monitoring system(described as OneTouch Select Plus below) is met if the lay user and HCP results obtained with OneTouch Select Plus meet the requirement stated in section 7.4.1 of ISO () 15197:2003(E). Further to meet the requirements of ISO 15197:2013(E) , the lay user results obtained with OneTouch Select Plus should meet the requirements stated in section 8.2 of ISO 15197:2013(E). The effectiveness of instructions for use is met , if for each item on the Instructions for Use Questionnaire, the 90% lower confidence limit (90% LCL) for the correct response rate is equal to or greater than 70%.
Study Design and subject population:
This study is an open, non-randomized clinical evaluation and will be conducted at a minimum of 2 sites in China. At least 240 evaluable diabetic subjects who meet the enrolment criteria will participate in this evaluation.
Study procedures:
- Each potential Subject (or legally authorized representative) reads and signs the Informed Consent Form, and receives a signed copy.
- After completing an in-clinic familiarization session, the Subject lances a fingertip, obtains a drop of blood large enough for two meter tests, and performs a self-test using OneTouch Select Plus BGMS.
- Study staff immediately performs a blood glucose test from the same blood drop with a second set of OneTouch Select Plus BGMS with the same lot of test strips.
- Within 5 minutes of the Subject's self-lancing, study staff collects blood from the same finger puncture for hematocrit and reference plasma glucose testing (duplicate tests on the YSI 2300 performed by study staff).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Subject is at least 18 years of age.
- Subject has a current diagnosis of type 1 or type 2 diabetes mellitus.
- Subject is currently performing unassisted self-monitoring of blood glucose.
- Subject agrees to sign two (2) copies each of the Subject Informed Consent Form.
- Subject agrees to provide relevant demographic, medical history and diabetes management information and agrees to allow study staff access to medical records when necessary.
- Subject can read and understand Chinese.
- Subject agrees to complete all aspects of the study including at least one fingertip puncture, one retry in maximum may be performed if insufficient blood collected or an error message is obtained on the first attempt.
Exclusion Criteria:
- Subject is currently working for, has previously worked for, or has an immediate family member working for a company manufacturing and/or marketing blood glucose monitoring products.
- Subject has already participated in this study.
- Subject is knowingly pregnant.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
The accuracy of glucose results obtained from OneTouch Select Plus BGMS
Time Frame: instantly after Glucose testing
|
User Performance of the OneTouch Select® Plus Blood Glucose Monitoring system(described as OneTouch Select Plus below) is met if the lay user and HCP results obtained with OneTouch Select Plus meet the requirement stated in section 7.4.1 of ISO 15197:2003(E).Further to meet the requirements of ISO 15197:2013(E) , the lay user results obtained with OneTouch Select Plus should meet the requirements stated in section 8.2 of ISO 15197:2013(E).
|
instantly after Glucose testing
|
|
The correct response rate of Instructions for Use Questionnaire
Time Frame: instantly after Glucose testing
|
The effectiveness of instructions for use is met , if for each item on the Instructions for Use Questionnaire, the 90% lower confidence limit (90% LCL) for the correct response rate is equal to or greater than70%
|
instantly after Glucose testing
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- LFS-201601
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Blood Glucose Measurement
-
Johnson & Johnson Medical, ChinaCompletedBlood Glucose MeasurementChina
-
GlySureCompleted
-
West German Center of Diabetes and HealthBionorica SECompletedPostprandial Glucose Response | Glycaemic Index | Continous Glucose MeasurementGermany
-
National Heart Centre SingaporeNational Medical Research Council (NMRC), SingaporeRecruitingBlood Pressure Measurement | Blood Glucose MonitoringSingapore
-
Youngstown State UniversityMidlothian Free Health ClinicCompletedBlood Pressure MeasurementUnited States
-
Sensifree Ltd.CompletedBlood Pressure MeasurementUnited States
-
GE HealthcareCompleted
-
Sensifree Ltd.CompletedBlood Pressure MeasurementIsrael
-
Nevsehir Public HospitalCompletedBlood Pressure MeasurementTurkey (Türkiye)
-
Sensifree Ltd.Completed
Clinical Trials on OneTouch Select® Plus Glucose Test Strips
-
LifeScan Scotland LtdMAC Clinical ResearchCompleted
-
Ascensia Diabetes CareCompleted
-
Institut für Diabetes-Technologie Forschungs- und...BayerCompleted
-
Institut für Diabetes-Technologie Forschungs- und...Ascensia Diabetes CareCompleted
-
LifeScanEvidation HealthNot yet recruitingDiabetes Mellitus, Type 2United States
-
LifeScanCompletedDiabetes MellitusUnited Kingdom
-
Oregon Health and Science UniversityWashington University School of Medicine; Duke UniversityUnknownGestational Diabetes Mellitus as Antepartum ConditionUnited States
-
LifeScanUnknownDiabetes MellitusUnited States
-
Institut für Diabetes-Technologie Forschungs- und...LifeScanCompletedClinical System Accuracy Evaluation With OneTouch® Verio Flex Blood Glucose Monitoring System (BGMS)Diabetes MellitusGermany
-
University of Wisconsin, MadisonCompleted